Organizational Structure
BOARD OF DIRECTORS 2020 UC
TitularGuillermo Marshall Rivera (President)
Mónica Singer González
María Isabel Yuseff Sepúlveda
Álvaro Ossa Daruich
Mauricio Cuello Fredes
Substitute
Paulina Dreyer Arroyo
Gabriela Novoa Muñoz
Alexis Kalergis Parra
Claudio Parra Mora
Alejandro Corvalán
BOARD OF DIRECTORS 2020 ABOOTT
TitularJuan Roberto Sutelman
Lorena Galeotti
Agustín Eguiguren Correa
Julio Jiménez Doñas
Rosanna Vega Tomljenovic
Jorge Nieto
Substitute
Matías León Pérez de Arce
Carolina Briceño González
Álvaro Kauer Olguín
Julio Espinoza Ovalle
Patricio Mujica Barrientos
Viviana Ticona Weise
EXECUTIVE TEAM
"We aim to be a sustainable platform over time that will allow us to transfer to the market, top-level science and products that are beneficial to health, focusing on diagnostics, therapies and vaccines for our country and the world," says Rebecca Ibacache, General Manager of the Consortium.
Rebeca Ibacache General Manager
Katherine Gutiérrez Management Assistant
Mauricio Mieres Project Engineer
Emerson VargasChief of administration in finances
Carlos Alexis CatalánJunior Project Engineer
Macarena Rocio ArmijoProject Assistant
TECHNICAL COMMITTEE
The technical committee that supports BMRC is a group of people who play the role of overseeing, supporting and advising the scientific and intellectual property aspects of the projects in progress. This committee may put forward its vision or opinion on any aspect of the projects to the Consortium's board of directors, indicating strengths and weaknesses, as well as giving any suggestions aiming at improving them.
EXECUTIVE COMMITTEE
The executive committee is a group of people who have the role of supporting and targeting financial and administrative decision making to the BMRC management.
COMMERCIAL COMMITTEE
This Committee has been established to identify the best strategy for commercial launch that each of the projects must take in its advanced or final stage.
EXTERNAL ADVISERS
BMRC counts on an external advisory staff for the technical, administrative and commercial part of national and international affairs.
Read moreNancy J. Levy
Ph.D., Managing Partner Biohealth Management, LLC and Boston Landing, US
Nancy Levy, Ph.D., is a strategy and tactical business development and marketing consultant, facilitating growth of small and medium sized, international companies. She offers in-depth, hands-on consulting to define business and market strategies and their go-to-market implementation. In addition to her role with BostonLanding, Nancy is the Managing Partner of BioHealth Management LLC. She also serves on the boards of Acceleration Pharmaceuticals, Propel and on the board of advisers for SOM Biotech in Barcelona, Spain and is a member of the Newton-Wellesley Hospital Board of overseers. She is a mentor at the Venture Mentor Service (VMS) at MIT and a member of the VMS Outreach team, training other organizations to mentor. She is an adjunct professor at the Boston University School of Management and has been on the faculty at Harvard Medical School, where she also did her fellowship. She earned her Ph.D. from the University of Chicago.
DR. ALEXIS KALERGIS
Researcher
DR. ALEXIS KALERGIS
Doctor of Microbiology and Immunology at the Albert Einstein College of Medicine in New York, USA. He then completed two postdoctoral degrees, one at the Albert Einstein College of Medicine and another at The Rockefeller University, New York-USA. He is currently a Full Professor in the Department of Molecular Genetics and Microbiology at the Faculty of Biological Sciences and in the Department of Endocrinology at the Faculty of Medicine of the Catholic University of Chile.
He is also scientific adviser to the Senate and representative of the International Center for Molecular Genetics and Biotechnology in Chile. Dr. Kalergis will bring his expertise in transferring basic research to applications for the benefit of human health. He is a well-known researcher, won the award for the best doctoral thesis at the Albert Einstein College of Medicine, has trained hundreds of pre-and post-graduate students, many of whom currently hold academic positions in Chile and abroad.
Dr. Kalergis has delivered a hundred international conferences and published more than 160 articles in high impact journals such as Nature Immunology, PNAS and the Lancet. He has dozens of patent applications and has been awarded and funded by prestigious institutions in the USA, such as the Helen Hay Whitney Foundation, the Irvington Foundation and the Irene Diamond Foundation. He also received the award for the most outstanding young researcher in 2004 awarded by the Society of Biology and BiosChile IGSA. He has won national research funds such as Fondef, Fondecyt and the Millennium Scientific Initiative, as well as international ones such as the International Foundation of Science and the European Community. He currently serves as a board member of the Technological Consortium in Applied Molecular Clinical Biomedicine and as a director of the Millennium Institute in Immunology and Immunotherapy. Recently Dr. Kalergis was invited to join the Presidential Commission "Science for Development", which advises the President of the Republic on Science and Technology and on the design of the Ministry of Science and Technology.
Dr. CARLOS FARDELLA
Researcher
Dr. CARLOS FARDELLA
Physician-Surgeon at the University of Chile, specializing in Internal Medicine and Endocrinology at the Pontifical Catholic University of Chile, Post Doctorate in Molecular Biology from the University of California San Francisco (UCSF). World expert on the subject of Mineralocorticoid Hypertension for the Endocrine Society.
In the 1990s, he began as a researcher with the Fellowship of the National Institute of Health (NIH) and then obtained the scholarship from the Honorary President of the Republic of the Ministry of Development and Planning (MIDEPLAN).
During his training he received two awards: the Henry Christian Memorial Award for Excellence in Research, supported by the American Federation for Clinical Research (AFCR), Washington, USA and the Trainee Investigator Award supported by the Association of American Physicians (AAP), American Society for Clinical Investigation (ASCI) and the American Federation for Clinical Research (AFCR). Washington D.C., USA.
Returned to Chile in 1994 and developed the line of research on endocrine hypertension and metabolic syndromeby being awarded seven consecutive FONDECYT projects, two FONDEF projects, one CORFO project and one member of the Millennium Scientific Initiative (ICM).
In these two decades, his line has focused on the mechanisms and genes potentially involved in the emergence of hypertension and metabolic syndrome that has given rise to 130 ISI articles and more than 50 awards, both at national or international congresses.
On three occasions, he won the prize for best work published in Chile (awarded by the Medical Society 1994, 2001, 2014), twice the Excellence in Research award (awarded by the Universidad Católica in 1997 and 2012), the Academy Award for Medicine for the trajectory in research (2002) and recently the Prize for University Scientific Research granted by the El Mercurio newspaper and the Santander Bank.
In 2008 he was nominated a world expert in the topic of Hypertension Mineralocorticoidea, where he elaborated the guidelines for diagnosis and treatment of primary hyperaldosteronism together with a group of 8 experts appointed by the Endocrine Society.
Dr. Hernán González
Researcher
Dr. Hernán González
Hernán González, MD, PhD. Hernán González, MD, PhD. He is currently Associate Professor of Surgery in the Department of Surgical Oncology at the Pontificia Universidad Católica de Chile. He completed his clinical fellowship in head and neck surgery at the MD Anderson Cancer Center. Maintains active clinical practice in the surgical treatment of patients with thyroid cancer, with extensive experience in the management of advanced localized cancer and recurrent thyroid cancer.
For the past 5 years he has led a research team at the Biomedical Research Consortium (BMRC), focusing on translational research in cancer biomarkers. His group has created new bioinformatics methods that allow the development of high precision, but small sized, genetic signature tests that can be adapted to widely available diagnostic platforms. The first test, soon to be commercialized and called Thyroidprint®, is a genetic expression test that very accurately (NPV 98%) rules out the presence of thyroid cancer in indeterminate thyroid nodules. This signature uses 10 genes, operates on an FDA-approved qPCR platform and will be available as a diagnostic kit in treatment centres. A promising portfolio of new diagnostic and prognosis signatures is under development, including thyroid, lung and gastric cancer, thus increasing the supply of tests for personalized medicine.
Dr. González has recently founded the biotechnology startup, GeneproDX, which is a molecular diagnostics company based in Silicon Valley and Santiago - Chile, which will market new tests for personalized medicine used for the diagnosis and prognosis of solid tumors.
Dr. Gareth Owen
Researcher
Dr. Gareth Owen
Profesor asociado de la Facultad de Ciencias Biológicas y de la Facultad de Medicina de la Pontificia Universidad Católica de Chile.
Uno de los fundadores y de los principales investigadores del Consorcio de Biomédicina de Chile (BMRC)
Obtuvo su pregrado en el King´s College London y su Doctorado en Bioquímica en el Royal Postgraduate Medical School, Hospital Hammersmith, Imperial College London.
Realizó post-doctorados en la Universidad de Colorado, E.E.U.U y después en el Instituto de Investigación del Cáncer (ICR) en Londres, Reino Unido.
Su área de mayor interés es la investigación del cáncer, cuenta con una lista de numerosas publicaciones y 14 estudiantes de doctorado graduados.
www.labowen.cl
Además, es miembro de la comisión del Grupo Clínico de Investigación Oncológica de Chile (GOCCHI), sub-director del Centro UC para la Investigación en la Oncología (CITO) y líder de la División de Investigación para el Foro Nacional del Cáncer Chileno (FNC).
DRA. SUSAN BUENO
Researcher
DRA. SUSAN BUENO
Since 2007 to date she has been an associate professor at the School of Biological Sciences of the Pontificia Universidad Católica de Chile . Currently she is working in the Department of Molecular Genetics and Microbiology of the Faculty of Biological Sciences of the Pontificia Universidad Católica de Chile.
Dr. Bueno is a Medical Technologist and has taken courses in Medical Technology, has a Bachelor in Medical Technology with a Major in Clinical Laboratory, Blood Bank and Hematology (1994-1999, University of Chile); a PhD in Biomedical Sciences from the University of Chile (2000-2004, University of Chile); Postdoctoral training in the Department of Molecular Genetics and Microbiology, School of Biological Sciences (2004-2007, Pontificia Universidad Católica de Chile).
Her extensive laboratory experience includes: the Dr. Phillip Youderian Laboratory, Texas A & M University, College Station, Texas. May to July 2002; Dr. Glenn Fennelly Laboratory, Albert Einstein College of Medicine, New York. May to September 2005; Dr. William Jacobs Laboratory, Albert Einstein College of Medicine, New York. December 2008 to March 2009; Dr. Michael Dustin Laboratory, New York University, New York, February to March 2010. In addition to being involved in research grants since 2007 she has won several awards and scholarships for her outstanding work and has held conferences and seminars.
Organizational structure
BOARD OF DIRECTORS 2020 UC
Guillermo Marshall Rivera (President)
Mónica Singer González
María Isabel Yuseff Sepúlveda
Álvaro Ossa Daruich
Mauricio Cuello Fredes
BOARD OF DIRECTORS 2020 ABBOTT
TitularJuan Roberto Sutelman
Lorena Galeotti
Agustín Eguiguren Correa
Julio Jiménez Doñas
Rosanna Vega Tomljenovic
Jorge Nieto
Paulina Dreyer Arroyo
Gabriela Novoa Muñoz
Alexis Kalergis Parra
Claudio Parra Mora
Alejandro Corvalán
Substitute
Matías León Pérez de Arce
Carolina Briceño González
Álvaro Kauer Olguín
Julio Espinoza Ovalle
Patricio Mujica Barrientos
Viviana Ticona Weise
EXECUTIVE TEAM
"We aim to be a sustainable platform over time that will allow us to transfer to the market, top-level science and products that are beneficial to health, focusing on diagnostics, therapies and vaccines for our country and the world," says Rebecca Ibacache, General Manager of the Consortium.
Rebeca Ibacache General Manager
Katherine Gutiérrez Management Assistant
Mauricio Mieres Project Engineer
Emerson VargasChief of administration in finances
Carlos Alexis CatalánJunior Project Engineer
Macarena Rocio ArmijoProject Assistant
TECHNICAL COMMITTEE
The technical committee that supports BMRC is a group of people who play the role of overseeing, supporting and advising the scientific and intellectual property aspects of the projects in progress. This committee may put forward its vision or opinion on any aspect of the projects to the Consortium's board of directors, indicating strengths and weaknesses, as well as giving any suggestions aiming at improving them.
EXECUTIVE COMMITTEE
The executive committee is a group of people who have the role of supporting and targeting financial and administrative decision making to the BMRC management.
COMMERCIAL COMMITTEE
This Committee has been established to identify the best strategy for commercial launch that each of the projects must take in its advanced or final stage.
EXTERNAL ADVISERS
BMRC counts on an external advisory staff for the technical, administrative and commercial part of national and international affairs.
Nacy J. Levy
Nancy J. Levy
Ph.D., Managing Partner Biohealth Management, LLC and Boston Landing, US
Nancy Levy, Ph.D., is a strategy and tactical business development and marketing consultant, facilitating growth of small and medium sized, international companies. She offers in-depth, hands-on consulting to define business and market strategies and their go-to-market implementation. In addition to her role with BostonLanding, Nancy is the Managing Partner of BioHealth Management LLC. She also serves on the boards of Acceleration Pharmaceuticals, Propel and on the board of advisers for SOM Biotech in Barcelona, Spain and is a member of the Newton-Wellesley Hospital Board of overseers. She is a mentor at the Venture Mentor Service (VMS) at MIT and a member of the VMS Outreach team, training other organizations to mentor. She is an adjunct professor at the Boston University School of Management and has been on the faculty at Harvard Medical School, where she also did her fellowship. She earned her Ph.D. from the University of Chicago.
DR. ALEXIS KALERGIS
Researcher
DR. ALEXIS KALERGIS
Doctor of Microbiology and Immunology at the Albert Einstein College of Medicine in New York, USA. He then completed two postdoctoral degrees, one at the Albert Einstein College of Medicine and another at The Rockefeller University, New York-USA. He is currently a Full Professor in the Department of Molecular Genetics and Microbiology at the Faculty of Biological Sciences and in the Department of Endocrinology at the Faculty of Medicine of the Catholic University of Chile.
He is also scientific adviser to the Senate and representative of the International Center for Molecular Genetics and Biotechnology in Chile. Dr. Kalergis will bring his expertise in transferring basic research to applications for the benefit of human health. He is a well-known researcher, won the award for the best doctoral thesis at the Albert Einstein College of Medicine, has trained hundreds of pre-and post-graduate students, many of whom currently hold academic positions in Chile and abroad.
Dr. Kalergis has delivered a hundred international conferences and published more than 160 articles in high impact journals such as Nature Immunology, PNAS and the Lancet. He has dozens of patent applications and has been awarded and funded by prestigious institutions in the USA, such as the Helen Hay Whitney Foundation, the Irvington Foundation and the Irene Diamond Foundation. He also received the award for the most outstanding young researcher in 2004 awarded by the Society of Biology and BiosChile IGSA. He has won national research funds such as Fondef, Fondecyt and the Millennium Scientific Initiative, as well as international ones such as the International Foundation of Science and the European Community. He currently serves as a board member of the Technological Consortium in Applied Molecular Clinical Biomedicine and as a director of the Millennium Institute in Immunology and Immunotherapy. Recently Dr. Kalergis was invited to join the Presidential Commission "Science for Development", which advises the President of the Republic on Science and Technology and on the design of the Ministry of Science and Technology.
Dr. CARLOS FARDELLA
Researcher
Dr. CARLOS FARDELLA
Physician-Surgeon at the University of Chile, specializing in Internal Medicine and Endocrinology at the Pontifical Catholic University of Chile, Post Doctorate in Molecular Biology from the University of California San Francisco (UCSF). World expert on the subject of Mineralocorticoid Hypertension for the Endocrine Society.
In the 1990s, he began as a researcher with the Fellowship of the National Institute of Health (NIH) and then obtained the scholarship from the Honorary President of the Republic of the Ministry of Development and Planning (MIDEPLAN).
During his training he received two awards: the Henry Christian Memorial Award for Excellence in Research, supported by the American Federation for Clinical Research (AFCR), Washington, USA and the Trainee Investigator Award supported by the Association of American Physicians (AAP), American Society for Clinical Investigation (ASCI) and the American Federation for Clinical Research (AFCR). Washington D.C., USA.
Returned to Chile in 1994 and developed the line of research on endocrine hypertension and metabolic syndromeby being awarded seven consecutive FONDECYT projects, two FONDEF projects, one CORFO project and one member of the Millennium Scientific Initiative (ICM).
In these two decades, his line has focused on the mechanisms and genes potentially involved in the emergence of hypertension and metabolic syndrome that has given rise to 130 ISI articles and more than 50 awards, both at national or international congresses.
On three occasions, he won the prize for best work published in Chile (awarded by the Medical Society 1994, 2001, 2014), twice the Excellence in Research award (awarded by the Universidad Católica in 1997 and 2012), the Academy Award for Medicine for the trajectory in research (2002) and recently the Prize for University Scientific Research granted by the El Mercurio newspaper and the Santander Bank.
In 2008 he was nominated a world expert in the topic of Hypertension Mineralocorticoidea, where he elaborated the guidelines for diagnosis and treatment of primary hyperaldosteronism together with a group of 8 experts appointed by the Endocrine Society.
Dr. Hernán González
Researcher
Dr. Hernán González
Hernán González, MD, PhD. Hernán González, MD, PhD. He is currently Associate Professor of Surgery in the Department of Surgical Oncology at the Pontificia Universidad Católica de Chile. He completed his clinical fellowship in head and neck surgery at the MD Anderson Cancer Center. Maintains active clinical practice in the surgical treatment of patients with thyroid cancer, with extensive experience in the management of advanced localized cancer and recurrent thyroid cancer.
For the past 5 years he has led a research team at the Biomedical Research Consortium (BMRC), focusing on translational research in cancer biomarkers. His group has created new bioinformatics methods that allow the development of high precision, but small sized, genetic signature tests that can be adapted to widely available diagnostic platforms. The first test, soon to be commercialized and called Thyroidprint®, is a genetic expression test that very accurately (NPV 98%) rules out the presence of thyroid cancer in indeterminate thyroid nodules. This signature uses 10 genes, operates on an FDA-approved qPCR platform and will be available as a diagnostic kit in treatment centres. A promising portfolio of new diagnostic and prognosis signatures is under development, including thyroid, lung and gastric cancer, thus increasing the supply of tests for personalized medicine.
Dr. González has recently founded the biotechnology startup, GeneproDX, which is a molecular diagnostics company based in Silicon Valley and Santiago - Chile, which will market new tests for personalized medicine used for the diagnosis and prognosis of solid tumors.
Dr. Gareth Owen
Researcher
Dr. Gareth Owen
Profesor asociado de la Facultad de Ciencias Biológicas y de la Facultad de Medicina de la Pontificia Universidad Católica de Chile.
Uno de los fundadores y de los principales investigadores del Consorcio de Biomédicina de Chile (BMRC)
Obtuvo su pregrado en el King´s College London y su Doctorado en Bioquímica en el Royal Postgraduate Medical School, Hospital Hammersmith, Imperial College London.
Realizó post-doctorados en la Universidad de Colorado, E.E.U.U y después en el Instituto de Investigación del Cáncer (ICR) en Londres, Reino Unido.
Su área de mayor interés es la investigación del cáncer, cuenta con una lista de numerosas publicaciones y 14 estudiantes de doctorado graduados.
www.labowen.cl
Además, es miembro de la comisión del Grupo Clínico de Investigación Oncológica de Chile (GOCCHI), sub-director del Centro UC para la Investigación en la Oncología (CITO) y líder de la División de Investigación para el Foro Nacional del Cáncer Chileno (FNC).
DRA. SUSAN BUENO
Researcher
DRA. SUSAN BUENO
Since 2007 to date she has been an associate professor at the School of Biological Sciences of the Pontificia Universidad Católica de Chile . Currently she is working in the Department of Molecular Genetics and Microbiology of the Faculty of Biological Sciences of the Pontificia Universidad Católica de Chile.
Dr. Bueno is a Medical Technologist and has taken courses in Medical Technology, has a Bachelor in Medical Technology with a Major in Clinical Laboratory, Blood Bank and Hematology (1994-1999, University of Chile); a PhD in Biomedical Sciences from the University of Chile (2000-2004, University of Chile); Postdoctoral training in the Department of Molecular Genetics and Microbiology, School of Biological Sciences (2004-2007, Pontificia Universidad Católica de Chile).
Her extensive laboratory experience includes: the Dr. Phillip Youderian Laboratory, Texas A & M University, College Station, Texas. May to July 2002; Dr. Glenn Fennelly Laboratory, Albert Einstein College of Medicine, New York. May to September 2005; Dr. William Jacobs Laboratory, Albert Einstein College of Medicine, New York. December 2008 to March 2009; Dr. Michael Dustin Laboratory, New York University, New York, February to March 2010. In addition to being involved in research grants since 2007 she has won several awards and scholarships for her outstanding work and has held conferences and seminars.
- Av. Libertador Bernardo O'Higgins
- 440 piso 12, Santiago, Chile.
- Fono: (56) 223541958
- Email: info@bmrc.cl
- Derechos reservados
Av. Libertador Bernardo O'Higgins 440, piso 12, Santiago, chile.
Phone: (56) 223541958 / Email: info@bmrc.cl
all rights reserved